It has been proposed that the following characteristics are linked to a better prognosis: Low microvessel count; low VEGF expression; absence of the KRAS mutation; no overexpression of c-erbB-2; No EGFR expression; TTF-1 positivity; high level of p16 expression; low-class III β-tubulin expression, low or no ERCC1 expression (advanced NSCLC treated with platinum-based chemotherapy); in individuals who had their tumors removed; low survivin expression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.